UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 359

Sortiert nach

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Annals of oncology, 2019-10, Vol.30 (10), p.1613-1621

2019

Volltextzugriff (PDF)

Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes

Journal of endocrinological investigation, 2024-03

2024

Volltextzugriff (PDF)

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

Leukemia, 2014-07, Vol.28 (7), p.1529-1536

2014

Volltextzugriff (PDF)

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL‐102)

HemaSphere, 2022-06, Vol.6 (Suppl), p.994-995

2022

Volltextzugriff (PDF)

Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e273-e273

2015

Volltextzugriff (PDF)

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

Annals of oncology, 2023-10, Vol.34, p.S623-S624

2023

Volltextzugriff (PDF)

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

The New England journal of medicine, 2008-07, Vol.359 (1), p.31-42

2008

Volltextzugriff (PDF)

ZIO-101 (S-dimethylarsino-glutathione): Phase I/II trials in advanced/progressive multiple myeloma

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.8109-8109

2007

Volltextzugriff (PDF)

195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors

Immuno-oncology technology, 2022-12, Vol.16, p.100307, Article 100307

2022

Volltextzugriff (PDF)

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer

Annals of oncology, 2011-09, Vol.22 (9), p.2057-2067

2011

Volltextzugriff (PDF)

A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.9133-9133

2007

Volltextzugriff (PDF)

PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)

HemaSphere, 2019-06, Vol.3 (S1), p.319-n/a

2019

Volltextzugriff (PDF)

PF703 LONG‐TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM

HemaSphere, 2019-06, Vol.3 (S1), p.306-n/a

2019

Volltextzugriff (PDF)

5PSQ-117 Failure mode and effects criticality analysis: multicentric application on cancer chemotherapy process

European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A218-A219

2018

Volltextzugriff (PDF)

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Annals of oncology, 2019-10, Vol.30 (10), p.1613

2019

Volltextzugriff (PDF)

A phase I/II study of oral melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e18574-e18574

2011

Volltextzugriff (PDF)

S853 SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW‐UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES

HemaSphere, 2019-06, Vol.3 (S1), p.380-381

2019

Volltextzugriff (PDF)

A preliminary report of a phase II trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.18156-18156

2007

Volltextzugriff (PDF)

Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8070-8070

2011

Volltextzugriff (PDF)

A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8134-8134

2010

Volltextzugriff (PDF)

The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e13555-e13555

2011

Volltextzugriff (PDF)

A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #I-04–015)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.19018-19018

2008

Volltextzugriff (PDF)

A phase II trial of single-agent vinflunine as second-line treatment for advanced non-small cell lung cancer (An International Oncology Network Study, #I-05–009)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.19033-19033

2008

Volltextzugriff (PDF)

Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.10540-10540

2010

Volltextzugriff (PDF)

A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3064-3064

2011

Volltextzugriff (PDF)

1 – 25 von 359

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(205)
Mit Volltextzugriff
(198)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(233)
Technology
(131)
Engineering
(123)
Engineering, Electrical & Electronic
(122)
Humans
(107)
Life Sciences & Biomedicine
(97)
Female
(66)
Male
(63)
Middle Aged
(50)
Adult
(41)
Biological And Medical Sciences
(39)
Microwave Antennas
(38)
Aged
(37)
Medical Sciences
(32)
Antennas
(30)
Microwave Measurement
(26)
Oncology
(25)
Microwave Theory And Techniques
(22)
Risk Factors
(19)
Antenna Measurements
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL‐102)

Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

ZIO-101 (S-dimethylarsino-glutathione): Phase I/II trials in advanced/progressive multiple myeloma

195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer

A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia

PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)

PF703 LONG‐TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM

5PSQ-117 Failure mode and effects criticality analysis: multicentric application on cancer chemotherapy process

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

A phase I/II study of oral melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM)

S853 SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW‐UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES

A preliminary report of a phase II trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer

Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial

A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM)

The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors

A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #I-04–015)

A phase II trial of single-agent vinflunine as second-line treatment for advanced non-small cell lung cancer (An International Oncology Network Study, #I-05–009)

Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial

A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies

Aktive Filter

Suchergebnisse filtern